{
    "body": "What is the mechanism of action of ocrelizumab for treatment of multiple sclerosis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23448220", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23609782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22229582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24928997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24444048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24494635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24832354", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18951300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24090587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24579720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22766059", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24251808", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25732947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24001305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24032475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24707333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22171583", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23208729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25296871"
    ], 
    "ideal_answer": [
        "Ocrelizumab is a cytolytic monoclonal antibody that binds CD20 antigen present of B cells. It is approved for treatment of multiple sclerosis."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", 
        "http://www.biosemantics.org/jochem#4002285", 
        "http://www.disease-ontology.org/api/metadata/DOID:2377"
    ], 
    "type": "summary", 
    "id": "56c1f011ef6e394741000042", 
    "snippets": [
        {
            "offsetInBeginSection": 80, 
            "offsetInEndSection": 474, 
            "text": "Recent therapeutic advances include modifications to improve tolerability of existing products (e.g. interferon beta and glatiramer acetate), development of novel anti-neuroinflammatory medications (e.g. fingolimod, teriflunomide and dimethyl fumarate, daclizumab, alemtuzumab, ocrelizumab) and investigation of treatments in progressive MS (e.g. natalizumab, mastinib, natalizumab, siponimod).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24707333", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 630, 
            "offsetInEndSection": 772, 
            "text": "This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001305", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1123, 
            "offsetInEndSection": 1456, 
            "text": "Alemtuzumab, ocrelizumab and daclizumab respresent monoclonal antibodies in advanced stages of clinical development for their use in RRMS patients. Attempts to study the safety and efficacy of alemtuzumab and B cell-depleting anti-CD20 antibodies, i.e. rituximab, ocrelizumab or ofatumumab, in CIDP patients are currently under way. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24032475", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 675, 
            "offsetInEndSection": 940, 
            "text": "More recently, monoclonal antibodies have been engineered to act through specific mechanisms such as blocking alpha-4 integrin interactions (natalizumab) or lysing cells bearing specific markers, for example CD52 (alemtuzumab) or CD20 (ocrelizumab and ofatumumab). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24444048", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928997", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 491, 
            "offsetInEndSection": 738, 
            "text": "Today, there is broad experience with natalizumab and other MOAB (alemtuzumab, daclizumab, rituximab, ocrelizumab, ofatumumab and anti-lingo-1) that are pending commercialization or are under phase II or III of development with promising results. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25732947", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1314, 
            "offsetInEndSection": 1538, 
            "text": " To reduce the risk of infusion reactions and improve long-term tolerability, the human-derived components of the antibody have been increased to form humanized or human monoclonal antibodies like ocrelizumab and ofatumumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25296871", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1062, 
            "offsetInEndSection": 1149, 
            "text": "Ocrelizumab will likely also be licensed as a second-line therapy in highly active MS. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24579720", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 372, 
            "offsetInEndSection": 814, 
            "text": "This is because of: (i) patent expirations, (ii) the introduction of natalizumab, which targets the interaction between leukocytes and the blood-CNS barrier, (iii) the launch of three oral immunomodulatory drugs (fingolimod, dimethyl fumarate and teriflunomide), with another (laquinimod) under regulatory review and (iv) a number of immunomodulatory monoclonal antibodies (alemtuzumab, daclizumab and ocrelizumab) about to enter the market. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24251808", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1033, 
            "offsetInEndSection": 1579, 
            "text": "In this review, we further discuss evidence for B cell and Ig contribution to human MS and NMO pathogenesis, pro-inflammatory and regulatory B cell effector functions, impaired B cell immune tolerance, the B cell-fostering microenvironment in the CNS, and B cell-targeted therapeutic interventions for MS and NMO, including CD20 depletion (rituximab, ocrelizumab, and ofatumumab), anti-IL6-R (tocilizumab), complement-blocking (eculizumab), inhibitors of AQP4-Ig binding (aquaporumab, small molecular compounds), and BAFF/BAFF-R-targeting agents.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24832354", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 669, 
            "offsetInEndSection": 979, 
            "text": "The main efficacy and safety results of these drugs are reviewed in this paper. They can be classified into 2 groups: oral (fingolimod, laquinimod, teriflunomide, BG-12 [dimethyl fumarate], oral cladribine, dalfampridine) and monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22766059", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 700, 
            "offsetInEndSection": 883, 
            "text": "Daclizumab and ocrelizumab are monoclonal antibodies that have shown efficacy and acceptable safety profiles in phase 2 trials; both are under investigation in ongoing phase 3 trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090587", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 408, 
            "offsetInEndSection": 585, 
            "text": " As such, humoral targeted immunotherapies that are being developed for MS are discussed herein: rituximab, ocrelizumab, and ofatumumab show promise as B-cell depleting agents. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23208729", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 889, 
            "offsetInEndSection": 1052, 
            "text": " The section on anti-CD20 antibodies reviews Phase II results on ocrelizumab and ofatumumab, and discusses current perspectives of these antibodies for MS therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448220", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1655, 
            "offsetInEndSection": 1858, 
            "text": "Rituximab is unlikely to be developed further as its license will expire, but ocrelizumab, another monoclonal antibody directly targeting B cells, is currently in phase 2 development and looks promising.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23609782", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1228, 
            "offsetInEndSection": 1439, 
            "text": "In addition, oral laquinimod, several monoclonal antibodies (eg, alemtuzumab, daclizumab, and ocrelizumab), and other agents have shown preliminary beneficial results in relapsing MS in phase 3 clinical trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 614, 
            "offsetInEndSection": 1010, 
            "text": "They can be categorized according to their mode of action into compounds targeting (i) leukocyte migration into the CNS (natalizumab); (ii) cytolytic antibodies (rituximab, ocrelizumab, ofatumumab, alemtuzumab); or (iii) antibodies and recombinant proteins targeting cytokines and chemokines and their receptors (daclizumab, ustekinumab, atacicept, tabalumab [Ly-2127399], secukinumab [AIN457]). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171583", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 731, 
            "offsetInEndSection": 933, 
            "text": "The second concept is to deplete T cells and/or B cells from the peripheral circulation using highly specific monoclonal antibodies such as alemtuzumab (anti-CD52) or rituximab/ocrelizumab (anti-CD20). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22229582", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 936, 
            "offsetInEndSection": 1200, 
            "text": "More recently, monoclonal antibodies have been engineered to act through specific mechanisms such as blocking alpha-4 integrin interactions (natalizumab) or lysing cells bearing specific markers, for example CD52 (alemtuzumab) or CD20 (ocrelizumab and ofatumumab).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24444048", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 218, 
            "text": "Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai Pharmaceutical Co Ltd are developing ocrelizumab, a humanized mAb against CD20, for the potential treatment of inflammatory disorders and B-cell malignancies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951300", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 109, 
            "text": "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951300", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 246, 
            "offsetInEndSection": 421, 
            "text": "We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 84, 
            "offsetInEndSection": 260, 
            "text": "We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "abstract"
        }
    ]
}